REG - Trellus Health PLC - Appointment of Chief Financial Officer

Trellus HealthAnnouncement

01/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220801:nRSA3352Ua&default-theme=true

RNS Number : 3352U  Trellus Health PLC  01 August 2022

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Appointment of Chief Financial Officer

 

LONDON, U.K. AND NEW YORK, U.S. (1 August 2022). Trellus Health plc (AIM:
TRLS), which is commercializing a scientifically validated, resilience-based,
connected health solution for chronic condition management, announces the
appointment of Stephen ("Steve") Young as Interim Chief Financial Officer,
with immediate effect.

 

An experienced finance director and a member of the Chartered Institute of
Management Accountants (CIMA), Steve is taking over the role from Richard
Evans, whose interim contract has completed. Steve joins Trellus in a
non-Board capacity, and will work alongside Dr. Marla Dubinsky, CEO, Salim
Hamir, Company Secretary and Aled Stevenson, COO.

 

Steve has prior CFO experience at AIM-listed companies, having held the
position at both Pure Wafer plc and British Biocell International (formerly
BBI Holdings plc). Steve joins Trellus from Axiom Manufacturing Limited, a
contract electronic manufacturer, where he served as CFO and Company
Secretary, and Greeve Limited, where he served as a Director from 2016 to
2022.

 

Julian Baines, Non-executive Chairman, said: "We are delighted to welcome
Steve to Trellus Health; Steve has previously served as Chief Financial
Officer for AIM-listed companies, and this experience will be valuable to the
Company going forward. I would like to repeat our thanks to Richard Evans for
his contribution to the Company, following the completion of his contract
earlier this month."

 

For further information please contact:

 

 Trellus Health plc                                       www.trellushealth.com (http://www.trellushealth.com)
 Julian Baines, Chairman                                  Via Walbrook PR

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR Limited                                      Tel: 020 7933 8780 or trellus@walbrookpr.com (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen / Phillip Marriage              Mob: 07980 541 893 / 07748 651 727 / 07867 984 082

 

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (LSE: TRLS) is the first digital health company focused on the
intersection of chronic physical conditions and mental health. Trellus
Health integrates its proprietary resilience-based methodology with the
technology, tools and team to deliver a whole-person technology-enhanced
experience that results in relieving disease burden and promoting individual
health behaviors that enable thriving in the face of a chronic condition.
Through its TrellusElevate™ connected care platform and companion App, the
company addresses both clinical and behavioral health together, in context, to
improve outcomes and reduce healthcare costs for patients, employers, and the
healthcare system.

 

The Company is initially focused on Inflammatory bowel disease ("IBD"), which
includes the chronic incurable conditions of Crohn's Disease and ulcerative
colitis, but considers its approach to have potential utility and demand
across many chronic conditions, including Irritable Bowel Syndrome ("IBS").

 

The TrellusElevate™ platform is the Company's proprietary connected health
platform that incorporates the GRITT™ methodology and learnings on
resilience from clinical research and practice conducted at the Mount Sinai
IBD Center for more than five years. This proprietary, resilience-driven
methodology has been scientifically validated to demonstrate meaningful
improvements in patient outcomes, 71% reduction in Emergency Department
(A&E) visits, and 94% reduction in unplanned hospitalisations, which the
directors of the Company believe indicates the potential for significant cost
savings for healthcare payers. IBD patients treated using the methodology also
experienced a 49% reduction in required opioid use and a 73% reduction in
corticosteroid use 12 months following program completion

(source:  https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258) ).

 

The Company was founded by Mount Sinai faculty members Dr. Marla C. Dubinsky,
MD and Dr. Laurie Keefer, PhD, both with decades of combined experience in IBD
and psychogastroenterology, respectively. Trellus Health's patent-pending
GRITT™ resilience assessment and personalized treatment methodology was
developed and validated at the Mount Sinai Health System to build resilience
and wellness for improved outcomes at lower cost.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information on Trellus Health, visit:
www.trellushealth.com (http://www.trellushealth.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBLGDRUDDDGDC